Market Place
Sourcing Support
Aurion’s eye cell therapy improves vision in small study, plots Ph 3 trial
19 Dec 2024 //
ENDPTS
Aurion launches eye disease cell therapy in its first market
25 Sep 2024 //
BUSINESSWIRE
Aurion Biotech to Present at ESCRS and Ophthalmology European Futures Forum
03 Sep 2024 //
BUSINESSWIRE
Aurion Biotech Gets Breakthrough And Advanced Therapy Designation
19 Jun 2024 //
BUSINESSWIRE
Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
30 Apr 2024 //
BUSINESSWIRE
Aurion Biotech to Present Clinical Data at the 2024 ASCRS Annual Meeting
02 Apr 2024 //
BUSINESSWIRE
Aurion Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
28 Mar 2024 //
BUSINESSWIRE
Greg Kunst, CEO of Aurion Biotech, Receives Healthcare Leadership Award
07 Dec 2023 //
BUSINESSWIRE
Aurion Biotech Named “Regenerative Therapeutics Company Of The Year
08 Nov 2023 //
BUSINESSWIRE
Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial
24 Oct 2023 //
BUSINESSWIRE
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
23 Mar 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.